Abstract
Diabetic nephropathy is the most frequent cause of terminal kidney failure in industrialized countries. In addition, the manifestation of diabetic nephropathy is associated with a poor prognosis for affected patients. Current therapies are based on established pathophysiological models. However, despite reflecting significant progress in our understanding of diabetic nephropathy, the translational efforts fell short their expectations. The current review summarizes recent studies which provided new insights into established mechanisms (part 1) and studies identifying new candidate mechanisms (part 2) underlying diabetic nephropathy.
Key words
diabetes - nephropathy - disease mechanism
References
-
1
Caramori ML, Fioretto P, Mauer M.
Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions.
Diabetes.
2003;
52
1036-1040
-
2
Jerums G, Premaratne E, Panagiotopoulos S. et al .
New and old markers of progression of diabetic nephropathy.
Diabetes Res Clin Pract.
2008;
82
(S 01)
S30-S37
-
3
Mauer M, Zinman B, Gardiner R. et al .
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
N Engl J Med.
2009;
361
40-51
-
4
Perkins BA, Ficociello LH, Silva KH. et al .
Regression of microalbuminuria in type 1 diabetes.
N Engl J Med.
2003;
348
2285-2293
-
5
Hovind P, Tarnow L, Parving HH.
Remission and regression of diabetic nephropathy.
Curr Hypertens Rep.
2004;
6
377-382
-
6
Gaede P, Tarnow L, Vedel P. et al .
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.
Nephrol Dial Transplant.
2004;
19
2784-2788
-
7
Holman RR, Paul SK, Bethel MA. et al .
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
N Engl J Med.
2008;
359
1565-1576
-
8
Fioretto P, Caramori ML, Mauer M.
The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007.
Diabetologia.
2008;
51
1347-1355
-
9
Dummy EDIC.
Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.
JAMA.
2003;
290
2159-2167
-
10
Holman RR, Paul SK, Bethel MA. et al .
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med.
2008;
359
1577-1589
-
11
Chen HQ, Veluthakal R, Palanivel R. et al .
GTP-binding protein-independent potentiation by mastoparan of IL-1beta-induced nitric oxide release from insulin-secreting HIT-T15 cells.
Apoptosis.
2004;
9
145-148
-
12
Ihnat MA, Thorpe JE, Kamat CD. et al .
Reactive oxygen species mediate a cellular ‘memory’ of high glucose stress signalling.
Diabetologia.
2007;
50
1523-1531
-
13
El-Osta A, Brasacchio D, Yao D. et al .
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia.
J Exp Med.
2008;
205
2409-2417
-
14
Toyoda M, Najafian B, Kim Y. et al .
Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy.
Diabetes.
2007;
56
2155-2160
-
15
Fioretto P, Steffes MW, Mauer M.
Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria.
Diabetes.
1994;
43
1358-1364
-
16
Caramori ML, Kim Y, Huang C. et al .
Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes.
Diabetes.
2002;
51
506-513
-
17
Pagtalunan ME, Miller PL, Jumping-Eagle S. et al .
Podocyte loss and progressive glomerular injury in type II diabetes.
J Clin Invest.
1997;
99
342-348
-
18
Langham RG, Kelly DJ, Cox AJ. et al .
Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition.
Diabetologia.
2002;
45
1572-1576
-
19
Wharram BL, Goyal M, Wiggins JE. et al .
Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene.
J Am Soc Nephrol.
2005;
16
2941-2952
-
20
Kalluri R.
Proteinuria with and without renal glomerular podocyte effacement.
J Am Soc Nephrol.
2006;
17
2383-2389
-
21
Jarad G, Miner JH.
Albuminuria, wherefore art thou?.
J Am Soc Nephrol.
2009;
20
455-457
-
22
Russo LM, Sandoval RM, Campos SB. et al .
Impaired tubular uptake explains albuminuria in early diabetic nephropathy.
J Am Soc Nephrol.
2009;
20
489-494
-
23
Lindenmeyer MT, Kretzler M, Boucherot A. et al .
Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy.
J Am Soc Nephrol.
2007;
18
1765-1776
-
24
Sato W, Kosugi T, Zhang L. et al .
The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy.
Lab Invest.
2008;
88
949-961
-
25
Brownlee M.
Biochemistry and molecular cell biology of diabetic complications.
Nature.
2001;
414
813-820
-
26
Hammes HP, Du X, Edelstein D. et al .
Benfotiamine blocks 3 major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.
Nat Med.
2003;
9
294-299
-
27
Asaba K, Tojo A, Onozato ML. et al .
Effects of NADPH oxidase inhibitor in diabetic nephropathy.
Kidney Int.
2005;
67
1890-1898
-
28
Thallas-Bonke V, Thorpe SR, Coughlan MT. et al .
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
Diabetes.
2008;
57
460-469
-
29
Fujii J, Myint T, Okado A. et al .
Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components.
Nephrol Dial Transplant.
1996;
11
(S 05)
34-40
-
30
Bierhaus A, Humpert PM, Morcos M. et al .
Understanding RAGE, the receptor for advanced glycation end products.
J Mol Med.
2005;
83
876-886
-
31
Forbes JM, Fukami K, Cooper ME.
Diabetic nephropathy: where hemodynamics meets metabolism.
Exp Clin Endocrinol Diabetes.
2007;
115
69-84
-
32
Shankar A, Klein R, Klein BE. et al .
Association between glycosylated hemoglobin level and 16-year incidence of chronic kidney disease in type 1 diabetes.
Exp Clin Endocrinol Diabetes.
2007;
115
203-206
-
33
Coughlan MT, Thorburn DR, Penfold SA. et al .
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes.
J Am Soc Nephrol.
2009;
20
742-752
-
34
Bohlender JM, Franke S, Stein G. et al .
Advanced glycation end products and the kidney.
Am J Physiol Renal Physiol.
2005;
289
F645-F659
-
35
Wendt TM, Tanji N, Guo J. et al .
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.
Am J Pathol.
2003;
162
1123-1137
-
36
Muller-Krebs S, Kihm LP, Zeier B. et al .
Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure.
Eur J Clin Invest.
2008;
38
296-305
-
37
Stopper H, Schinzel R, Sebekova K. et al .
Genotoxicity of advanced glycation end products in mammalian cells.
Cancer Lett.
2003;
190
151-156
-
38
Coughlan MT, Thorburn DR, Penfold SA. et al .
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes.
J Am Soc Nephrol.
2009;
20
742-752
-
39
Usui HK, Shikata K, Sasaki M. et al .
Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation.
Diabetes.
2007;
56
363-372
-
40
Morcos M, Sayed AA, Bierhaus A. et al .
Activation of tubular epithelial cells in diabetic nephropathy.
Diabetes.
2002;
51
3532-3544
-
41
Morcos M, Schlotterer A, Sayed AA. et al .
Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells.
Horm Metab Res.
2008;
40
752-759
-
42
Oldfield MD, Bach LA, Forbes JM. et al .
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).
J Clin Invest.
2001;
108
1853-1863
-
43
Lu YL, Jimbu YM, Chen Y. et al .
The effects of rosiglitazione on renal artery endothelium in diabetic rats.
Exp Clin Endocrinol Diabetes.
2008;
116
537-540
-
44
Miyata T, Van Ypersele De SC, Ueda Y. et al .
Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms.
J Am Soc Nephrol.
2002;
13
2478-2487
-
45
Sun HL, Sun L, Li YY. et al .
ACE-inhibitor suppresses the apoptosis induced by endoplasmic reticulum stress in renal tubular in experimental diabetic rats.
Exp Clin Endocrinol Diabetes.
2009;
117
336-344
-
46
Kakoki M, Takahashi N, Jennette JC. et al .
Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor.
Proc Natl Acad Sci USA.
2004;
101
13302-13305
-
47
Allard J, Buleon M, Cellier E. et al .
ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats.
Am J Physiol Renal Physiol.
2007;
293
F1083-F1092
-
48
Bodin S, Chollet C, Goncalves-Mendes N. et al .
Kallikrein protects against microalbuminuria in experimental type I diabetes.
Kidney Int.
2009;
76
395-403
-
49
Mann JF, Schmieder RE, McQueen M. et al .
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Lancet.
2008;
372
547-553
-
50
Ishii H, Jirousek MR, Koya D. et al .
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor.
Science.
1996;
272
728-731
-
51
Meier M, Menne J, Haller H.
Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice.
Diabetologia.
2009;
52
765-775
-
52
Meier M, Menne J, Park JK. et al .
Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo.
J Am Soc Nephrol.
2007;
18
1190-1198
-
53
Sharma K, Jin Y, Guo J. et al .
Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.
Diabetes.
1996;
45
522-530
-
54
Ziyadeh FN, Hoffman BB, Han DC. et al .
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
Proc Natl Acad Sci USA.
2000;
97
8015-8020
-
55
Ohtomo S, Izuhara Y, Takizawa S. et al .
Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.
Kidney Int.
2007;
72
1512-1519
-
56
Caramori ML, Fioretto P, Mauer M.
Enhancing the predictive value of urinary albumin for diabetic nephropathy.
J Am Soc Nephrol.
2006;
17
339-352
Correspondence
Dr. B. Isermann
Universität Heidelberg
Innere Medizin I
INF 410
69120 Heidelberg
Germany
Phone: +49/06221/563 8608
Fax: +49/06221/564 233
Email: berend.isermann@med.uni-heidelberg.de
